Sebastian Gensior

April 5–10, 2026 saw $9.2 billion in confirmed capital deployed across biopharma, spanning 6 M&A transactions, 6 licensing deals, 3 structured debt/royalty facilities, 14 equity raises, 2 government contracts, and 1 fund close — plus 7 clinical readouts and 5 regulatory actions. Oncology dominated at $3.

The term "Royalty Interest Agent" does not appear as a standardised designation in pharmaceutical royalty financing documentation. Instead, the role is expressed through a set of functionally equivalent but terminologically inconsistent defined terms that vary by transaction, by investor, and by deal counsel. Understanding what this role entails—

Coefficient Bio was a New York-based stealth AI-biotech startup founded in September 2025. On April 3, 2026, Anthropic — the San Francisco-based AI safety company behind the Claude family of models — acquired Coefficient Bio in an all-stock deal valued at just over $400 million. The company had fewer than ten employees,

Overview and Investment Focus Catalio Capital Management is not a traditional venture capital firm — it is a scientist-entrepreneur network turned multi-strategy investment platform. Founded in 2020 by George Petrocheilos and Dr. R. Jacob Vogelstein, and spun out of Camden Partners Holdings, the New York-based firm has built what may be

Pharmaceutical licensing agreements are complex instruments designed to allocate risk between parties with fundamentally different positions. The licensor—often a biotech startup or university—has developed valuable intellectual property but may lack commercial capabilities. The licensee—typically a larger pharmaceutical company—has the infrastructure to commercialize but faces uncertainty about

When Editas Medicine sold its future Cas9 licence fees to a DRI Healthcare subsidiary for $57 million upfront, the transaction crystallised something that pharmaceutical royalty practitioners have long understood but rarely said out loud: reach-through royalties are not "royalties on the tool." They are engineered downstream participation — a

The hybrid instrument that sits at the intersection of debt, royalty, and equity — how it functions, why it is gaining traction, and what CFOs and investors need to understand about its structural mechanics.

W14 (March 29–April 5, 2026) opened with the formal announcement of the week's headline deal: Eli Lilly's $2.75 billion global R&D collaboration with Insilico Medicine, upgrading the FT-previewed $2 billion GLP-1 license reported in W13 into a broader, multi-target AI drug discovery

When Blackstone closed a $1.47 billion asset-backed securitisation backed by royalties from 45,000 songs in November 2024, 25 institutional investors participated in a single rated issuance structured by MUFG, with Barclays, Goldman Sachs, Fifth Third Securities and SMBC Nikko as joint bookrunners. The notes were rated A- by

Alteogen Inc. (KOSDAQ: 196170) is a South Korean biopharmaceutical platform company founded in 2008 and headquartered in Daejeon. It operates across three distinct lines of business: subcutaneous drug delivery technology licensing under the Hybrozyme™ platform, next-generation biologic drug development using the NexP™ and NexMab™ platforms, and biosimilar commercialisation via its